Takeda presents orexin data from landmark oveporexton (tak-861) phase 3 program in narcolepsy type 1 at world sleep 2025

Singapore & osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) will present data from two global phase 3 double-blind, placebo-controlled studies of oveporexton (tak-861)1, a potential first-in-class investigational oral orexin receptor 2 (ox2r)-selective agonist in narcolepsy type 1 (nt1), during multiple oral presentations at the world sleep 2025 congress in singapore beginning at 3:15 p.m. sgt today. both the firstlight (tak-861-3001) and radiantlight (tak-861-3002).
TAK Ratings Summary
TAK Quant Ranking